U.S. Stock Market Midday Update

Windtree Therapeutics fell 9.06%, with increased trading volume. Based on recent important news:

1. On July 29, investors chose to redeem or convert most of the Series C and D preferred shares, leading to a 9.06% drop in stock price.

2. On July 28, Redfin data showed a surge in listings in Las Vegas, with sales plummeting, increasing market uncertainty and affecting investor confidence.

3. On July 30, the transaction volume for properties priced at HKD 6 million or below reached a record high, reflecting market preference for low-priced properties, indirectly impacting the performance of related stocks.

Stocks with High Trading Volume in the Industry

Soligenix rose 312.01%, with a trading volume of 678 million. Based on recent important news:

1. On July 31, Soligenix announced that SGX945 showed biological efficacy in the Phase II clinical trial for treating Behçet's disease, with no adverse events, causing the stock price to surge by 312.01%.

2. On July 31, research results indicated that SGX945 has further development potential in the orphan disease field, leading to market optimism about its future prospects and driving up the stock price.

3. On July 31, SGX945 showed a 40% ulcer reduction rate in Week 4, surpassing the 37% of the competing drug apremilast, further boosting market recognition of its efficacy and stock price.

AbbVie rose 2.79%, with increased trading volume. Based on recent important news:

1. On July 31, AbbVie reported better-than-expected second-quarter results and raised its full-year earnings forecast, pushing the stock price up by 2.79%.

2. On July 31, AbbVie announced acquisition negotiations with Gilgamesh Pharmaceuticals to further expand its product line.

3. On July 31, AbbVie's Skyrizi and Rinvoq drug sales saw significant growth, increasing by 62% and 42% year-over-year, respectively.

Alnylam Pharmaceuticals rose 16.28%, with increased trading volume. Based on recent important news:

1. On July 31, Alnylam Pharmaceuticals raised its full-year revenue forecast, leading to a 16% increase in stock price.

2. On July 31, Alnylam Pharmaceuticals' Q2 net product revenue exceeded expectations, reaching USD 774 million.

3. On July 31, Alnylam Pharmaceuticals' adjusted operating revenue was USD 95.481 million.

Stocks with High Market Capitalization in the Industry

Amgen fell 0.30%, with increased trading volume. Based on recent important news:

1. On July 29, MarketBeat analysts did not include Amgen in their recommended stock list, leading to a cautious market attitude and a 0.30% decline in stock price.

2. On July 28, Amgen was listed as one of the Dow Jones dividend stocks, but despite a strong drug development pipeline, increased competition affected market confidence On July 28, Amgen is seeking breakthrough drugs to cope with biosimilar competition, and the market holds a cautious attitude towards its future growth